Zelboraf (vemurafenib) / Daiichi Sankyo, Roche  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zelboraf (vemurafenib) / Roche
COLUMBUS, NCT01909453 / 2013-001176-38: Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Checkmark 5 year data from COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma
Jul 2022 - Jul 2022: 5 year data from COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma
Checkmark Update on OS data of COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma at ASCO 2019 [screenshot]
May 2019 - Jun 2019: Update on OS data of COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma at ASCO 2019 [screenshot]
Checkmark From COLUMBUS trial in combination with binimetinib at SMR 2018 [screenshot]
More
Completed
3
921
Europe, Canada, Japan, US, RoW
LGX818, MEK162, vemurafenib, Zelboraf, PLX4032, RO5185426
Pfizer
Melanoma
11/16
09/24
IMspire150, NCT02908672 / 2016-002482-54: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Checkmark Submission of Cotellic + Tecentriq + Zelboraf in BRAFmut melanoma
Feb 2021 - Feb 2021: Submission of Cotellic + Tecentriq + Zelboraf in BRAFmut melanoma
Checkmark Data from IMspire150 trial in combination with Cotellic and Zelboraf for 1L melanoma
Nov 2020 - Nov 2020: Data from IMspire150 trial in combination with Cotellic and Zelboraf for 1L melanoma
Checkmark Approved in US in combination with Zelboraf and Tecentriq for 1L+ BRAFm melanoma
More
Completed
3
514
Europe, Canada, US, RoW
Atezolizumab, Atezolizumab Placebo, Cobimetinib, Vemurafenib, Vemurafenib Placebo
Hoffmann-La Roche
Melanoma
10/19
07/24
NCT05540951: VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Recruiting
3
78
RoW
VIC, Bevacizumab Plus Chemotherapy
Fudan University
Colorectal Cancer
08/22
12/22
NCT06008119: Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Not yet recruiting
3
165
NA
Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
Shanghai Kechow Pharma, Inc.
Colorectal Cancer Metastatic
12/26
12/26
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
BFAST, NCT03178552 / 2017-000076-28: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Checkmark Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Sep 2021 - Sep 2021: Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Hourglass Apr 2021 - Jun 2021 : First-patient-in for cohort F of P2/3 B-FAST trial for NSCLC
Recruiting
2/3
1000
Europe, Canada, Japan, US, RoW
Alectinib, RO5424802, Atezolizumab, RO5541267, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, RO7102122, Cobimetinib, RO5514041, Vemurafenib, RO5185426, Bevacizumab, RO4876646, Divarasib, RO7435846; GDC-6036, Docetaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer
08/28
08/28
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29

Download Options